Geoffrey Porges, MBBS
Director of Therapeutics Research, Diversified Biopharma
Dr. Porges is the Director of Therapeutics Research and a Senior Research Analyst at SVB Leerink covering Diversified Biopharmaceutical stocks. He brings to the firm over 25 years of expertise in advisory, executive and investment roles in the biopharmaceutical industry.
Prior to joining the firm in 2015, Dr. Porges established biotechnology research coverage at Sanford C. Bernstein where he became one of the most respected independent analysts of the industry. Prior to that, Dr. Porges served as Chief Operating Officer at BTG PLC and previously served in a variety of positions at Merck & Co, including Head of Worldwide Marketing in the Vaccine Division at Merck & Co.
Dr. Porges has been consistently ranked as one of Wall Street’s most influential biotechnology analysts. He is a frequent media contributor regarding investment opportunities, and risks, in the biopharmaceutical sector and his research covers the gamut from breakthrough scientific advances and early development programs to industry structure, strategy and valuation.
Dr. Porges earned his medical degree from the University of Sydney and trained in pediatric and internal medicine in Australia. He is also a graduate of Harvard Business School, where he was a Baker Scholar.